Aditivos inmunoestimulantes en la dieta de especies de tilapias (Oreochromis ssp.)

Background: Some diet additives have become alternatives to achieve higher yields within the productively sustainable, organic, and ecological margins. Hence, nutrients and microorganisms can be added to the diet for fish immunity improvements, by using the nutrients in the feed, which lead to a positive animal performance. Accordingly, the aim of this paper was to gather information related to the utilization of additives as immunostimulant in tilapia (Oreochromis ssp.), and their physiological performance in the body. Development: Many of these immunostimulants are microorganisms or habitual nutrients in the diet, such as polysaccharides, proteins or lipids, which at high concentrations are capable of creating a stimulating effect, speeding disease resistance through specific or unspecific mechanisms of immunological response, thus becoming primary prophylactic agents. Conclusions: The use of additives as immunostimulants helps prevent the occurrence of common diseases in tilapia culture, by modulating the intestinal system in the different species of genus Oreochromis, thus enhancing the unspecific immune response, and, in turn, some processes like individual growth, feeding efficiency, and stress tolerance can be favored. Key words: stimulating effect, additives, tilapia (Source: AGROVOC)  Antecedentes: Algunos aditivos alimentarios se han vuelto en la actualidad alternativas a discrepancias tales como la búsqueda de mejores rendimientos manteniéndose dentro de los márgenes productivamente sustentables, orgánicos y ecológicos. De esta manera se incorporan nutrientes y microorganismos a la dieta como una forma alternativa de mejorar la inmunidad de los peces, aprovechando los nutrientes en el alimento y actuando positivamente en el desempeño de los animales. El objetivo del presente trabajo fue recopilar información referente al uso de aditivos inmunoestimulantes en Tilapias (Oreochromis ssp.) y su desempeño fisiológico en el organismo. Desarrollo: Muchos de estos inmunoestimulantes existentes son microorganismos o nutrientes habituales de la dieta como son los polisacáridos, proteínas o lípidos, que suministrados en concentraciones elevadas tienen la capacidad producir un efecto estimulante acelerando la resistencia a las enfermedades mediante mecanismos específicos o inespecíficos de la respuesta inmunológica, convirtiéndose en agentes primarios profilácticos. Conclusiones: El empleo de aditivos inmunoestimulantes posibilita la prevención de enfermedades comunes en el cultivo de tilapias por medio de la modulación del ambiente intestinal en las diferentes especies del género Oreochromis mejorando la respuesta inmune inespecífica y a su vez se favorecen algunos procesos tales como el crecimiento individual, la eficiencia alimenticia y la tolerancia al estrés. Palabras clave: aditivos, efecto estimulante, tilapias (Fuente: AGROVOC

Aditivos inmunoestimulantes en la dieta de especies de tilapias (Oreochromis ssp.)

Antecedentes: Algunos aditivos alimentarios se han vuelto en la actualidad alternativas a discrepancias tales como la búsqueda de mejores rendimientos manteniéndose dentro de los márgenes productivamente sustentables, orgánicos y ecológicos. De esta manera se incorporan nutrientes y microorganismos a la dieta como una forma alternativa de mejorar la inmunidad de los peces, aprovechando los nutrientes en el alimento y actuando positivamente en el desempeño de los animales. El objetivo del presente trabajo fue recopilar información referente al uso de aditivos inmunoestimulantes en Tilapias (Oreochromis ssp.) y su desempeño fisiológico en el organismo. Desarrollo: Muchos de estos inmunoestimulantes existentes son microorganismos o nutrientes habituales de la dieta como son los polisacáridos, proteínas o lípidos, que suministrados en concentraciones elevadas tienen la capacidad producir un efecto estimulante acelerando la resistencia a las enfermedades mediante mecanismos específicos o inespecíficos de la respuesta inmunológica, convirtiéndose en agentes primarios profilácticos. Conclusiones: El empleo de aditivos inmunoestimulantes posibilita la prevención de enfermedades comunes en el cultivo de tilapias por medio de la modulación del ambiente intestinal en las diferentes especies del género Oreochromis mejorando la respuesta inmune inespecífica y a su vez se favorecen algunos procesos tales como el crecimiento individual, la eficiencia alimenticia y la tolerancia al estrés

PLANEACIÓN DIDÁCTICA GENERAL DE LA ASIGNATURA: FILOSOFÍA

GUÍA DIDÁCTICA / PLANEACIÓN DIDÁCTICA (NMS

Interferometric orbit determination system for geosynchronous SAR missions: experimental proof of concept

Future Geosynchronous Synthetic Aperture Radar (GEOSAR) missions will provide permanent monitoring of continental areas of the planet with revisit times of less than 24 h. Several GEOSAR missions have been studied in the USA, Europe, and China with different applications, including water cycle monitoring and early warning of disasters. GEOSAR missions require unprecedented orbit determination precision in order to form focused Synthetic Aperture Radar (SAR) images from Geosynchronous Orbit (GEO). A precise orbit determination technique based on interferometry is proposed, including a proof of concept based on an experimental interferometer using three antennas separated 10–15 m. They provide continuous orbit observations of present communication satellites operating at GEO as illuminators of opportunity. The relative phases measured between the receivers are used to estimate the satellite position. The experimental results prove the interferometer is able to track GEOSAR satellites based on the transmitted signals. This communication demonstrates the consistency and feasibility of the technique in order to foster further research with longer interferometric baselines that provide observables delivering higher orbital precision.This work has been supported by the Spanish Science, Research and Innovation Plan (MICINN) with Project Codes TEC2017-85244-C2-2-P and PID2020-117303GB-C21 and by Unidad de Excelencia Maria de Maeztu MDM-2016-0600 financed by the Agencia Estatal de Investigación, Spain.Peer ReviewedPostprint (published version

On The GeV & TeV Detections of the Starburst Galaxies M82 & NGC 253

The GeV and TeV emission from M82 and NGC 253 observed by Fermi, HESS, and VERITAS constrains the physics of cosmic rays (CRs) in these dense starbursts. We argue that the gamma rays are predominantly hadronic in origin, as expected by previous studies. The measured fluxes imply that pionic losses are efficient for CR protons in both galaxies: we show that a fraction F_cal ~ 0.2 - 0.4 of the energy injected in high energy primary CR protons is lost to inelastic proton-proton collisions (pion production) before escape, producing gamma rays, neutrinos, and secondary electrons and positrons. We discuss the factor ~2 uncertainties in this estimate, including supernova rate and leptonic contributions to the GeV-TeV emission. We argue that gamma-ray data on ULIRGs like Arp 220 can test whether M82 and NGC 253 are truly calorimetric, and we present upper limits on Arp 220 from the Fermi data. We show that the observed ratio of the GeV to GHz fluxes of the starbursts suggests that non-synchrotron cooling processes are important for cooling the CR electron/positron population. We briefly reconsider previous predictions in light of the gamma-ray detections, including the starburst contribution to the gamma-ray background and CR energy densities. Finally, as a guide for future studies, we list the brightest star-forming galaxies on the sky and present updated predictions for their gamma-ray and neutrino fluxes.Comment: 15 pages, emulateapj format, accepted to ApJ, Table 1 fixe

Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

A better understanding of schizophrenia subtypes is necessary to stratify the patients according to clinical attributes. To explore the genomic architecture of schizophrenia symptomatology, we analyzed blood co-expression modules and their association with clinical data from patients in remission after a first episode of schizophrenia. In total, 91 participants of the 2EPS project were included. Gene expression was assessed using the Clariom S Human Array. Weighted-gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its correlation with global functioning, clinical symptomatology, and premorbid adjustment. Among the 25 modules identified, six modules were significantly correlated with clinical data. These modules could be clustered in two groups according to their correlation with clinical data. Hub genes in each group showing overlap with risk genes for schizophrenia were enriched in biological processes related to metabolic processes, regulation of gene expression, cellular localization and protein transport, immune processes, and neurotrophin pathways. Our results indicate that modules with significant associations with clinical data showed overlap with gene sets previously identified in differential gene-expression analysis in brain, indicating that peripheral tissues could reveal pathogenic mechanisms. Hub genes involved in these modules revealed multiple signaling pathways previously related to schizophrenia, which may represent the complex interplay in the pathological mechanisms behind the disease. These genes could represent potential targets for the development of peripheral biomarkers underlying illness traits in clinical remission stages after a first episode of schizophrenia

Evaluation of integrated care services in Catalonia:population-based and service-based real-life deployment protocols

BackgroundComprehensive assessment of integrated care deployment constitutes a major challenge to ensure quality, sustainability and transferability of both healthcare policies and services in the transition toward a coordinated service delivery scenario. To this end, the manuscript articulates four different protocols aiming at assessing large-scale implementation of integrated care, which are being developed within the umbrella of the regional project Nextcare (2016-2019), undertaken to foster innovation in technologically-supported services for chronic multimorbid patients in Catalonia (ES) (7.5M inhabitants).Whereas one of the assessment protocols is designed to evaluate population-based deployment of care coordination at regional level during the period 2011-2017, the other three are service-based protocols addressing: i) Home hospitalization; ii) Prehabilitation for major surgery; and, iii) Community-based interventions for frail elderly chronic patients. All three services have demonstrated efficacy and potential for health value generation. They reflect different implementation maturity levels. While full coverage of the entire urban health district of Barcelona-Esquerra (520k inhabitants) is the main aim of home hospitalization, demonstration of sustainability at Hospital Clinic of Barcelona constitutes the core goal of the prehabilitation service. Likewise, full coverage of integrated care services addressed to frail chronic patients is aimed at the city of Badalona (216k inhabitants).MethodsThe population-based analysis, as well as the three service-based protocols, follow observational and experimental study designs using a non-randomized intervention group (integrated care) compared with a control group (usual care) with a propensity score matching method. Evaluation of cost-effectiveness of the interventions using a Quadruple aim approach is a central outcome in all protocols. Moreover, multi-criteria decision analysis is explored as an innovative method for health delivery assessment. The following additional dimensions will also be addressed: i) Determinants of sustainability and scalability of the services; ii) Assessment of the technological support; iii) Enhanced health risk assessment; and, iv) Factors modulating service transferability.DiscussionThe current study offers a unique opportunity to undertake a comprehensive assessment of integrated care fostering deployment of services at regional level. The study outcomes will contribute refining service workflows, improving health risk assessment and generating recommendations for service selection.Trials registrationNCT03130283 (date released 04/06/2018), NCT03768050 (date released 12/05/2018), NCT03767387 (date released 12/05/2018).</p

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

Background: Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients. Methods and Findings: Pilot, open-label, single arm clinical trial which involved 58 Caucasian HCV/HIV-coinfected patients who received weekly 135 μg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks after attaining undetectable viremia. The relationships between baseline patient-related variables, including IL28B genotype, plasma HCV-RNA, ribavirin dose/kg, peginterferon-α 2a and ribavirin levels with virological responses were analyzed. Only 4 patients showed lack of response and 5 patients dropped out due to adverse events related to the study medication. Overall, sustained virologic response (SVR) rates were 58.3% by intention-to-treat and 71.4% by per protocol analysis, respectively. Among patients with rapid virologic response (RVR), SVR and relapses rates were 92.6% and 7.4%, respectively. No relationships were observed between viral responses and ribavirin dose/kg, peginterferon-α 2a concentrations, ribavirin levels or rs129679860 genotype. Conclusions: Weekly 135 μg pegIFN-α 2a could be as effective as the standard 180 μg dose, with a very low incidence of severe adverse events. A 24-week treatment duration appears to be appropriate in patients achieving RVR, but extending treatment up to just 20 weeks beyond negativization of viremia is associated with a high relapse rate in those patients not achieving RVR. There was no influence of IL28B genotype on the virological responses. © 2012 López-Cortés et al.Funding provided by Fundación Pública Andaluza para la gestión de la Investigación en Salud de Sevilla. Hospitales Universitarios Virgen del Rocío. Seville, Spain. The enzyme-linked immunosorbent assay Hu-INF-α kits for determination of pegIFN-α-2a were financed by Roche Pharma, S.A. (Spain).Peer Reviewe

Fermi Observations of the Very Hard Gamma-ray Blazar PG 1553+113

We report the observations of PG 1553+113 during the first ~200 days of Fermi Gamma-ray Space Telescope science operations, from 4 August 2008 to 22 February 2009 (MJD 54682.7-54884.2). This is the first detailed study of PG 1553+113 in the GeV gamma-ray regime and it allows us to fill a gap of three decades in energy in its spectral energy distribution. We find PG 1553+113 to be a steady source with a hard spectrum that is best fit by a simple power-law in the Fermi energy band. We combine the Fermi data with archival radio, optical, X-ray and very high energy (VHE) gamma-ray data to model its broadband spectral energy distribution and find that a simple, one-zone synchrotron self-Compton model provides a reasonable fit. PG 1553+113 has the softest VHE spectrum of all sources detected in that regime and, out of those with significant detections across the Fermi energy bandpass so far, the hardest spectrum in that energy regime. Thus, it has the largest spectral break of any gamma-ray source studied to date, which could be due to the absorption of the intrinsic gamma-ray spectrum by the extragalactic background light (EBL). Assuming this to be the case, we selected a model with a low level of EBL and used it to absorb the power-law spectrum from PG 1553+113 measured with Fermi (200 MeV - 157 GeV) to find the redshift which gave the best fit to the measured VHE data (90 GeV - 1.1 TeV) for this parameterisation of the EBL. We show that this redshift can be considered an upper limit on the distance to PG 1553+113.Comment: Accepted for publication in the Astrophysical Journal (28 pages, 5 figures

Fermi LAT Observations of LS I +61 303: First detection of an orbital modulation in GeV Gamma Rays

This Letter presents the first results from the observations of LSI +61 303 using Large Area Telescope data from the Fermi Gamma-Ray Space Telescope between 2008 August and 2009 March. Our results indicate variability that is consistent with the binary period, with the emission being modulated at 26.6 +/- 0.5 days. This constitutes the first detection of orbital periodicity in high-energy gamma rays (20 MeV-100 GeV, HE). The light curve is characterized by a broad peak after periastron, as well as a smaller peak just before apastron. The spectrum is best represented by a power law with an exponential cutoff, yielding an overall flux above 100 MeV of 0.82 +/- 0.03(stat) +/- 0.07(syst) 10^{-6} ph cm^{-2} s^{-1}, with a cutoff at 6.3 +/- 1.1(stat) +/- 0.4(syst) GeV and photon index Gamma = 2.21 +/- 0.04(stat) +/- 0.06(syst). There is no significant spectral change with orbital phase. The phase of maximum emission, close to periastron, hints at inverse Compton scattering as the main radiation mechanism. However, previous very high-energy gamma ray (>100 GeV, VHE) observations by MAGIC and VERITAS show peak emission close to apastron. This and the energy cutoff seen with Fermi suggest the link between HE and VHE gamma rays is nontrivial.Comment: 7 pages, 5 figures, accepted for publication in ApJ Letters 21 July 200